

# Khaled M Musallam

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9065382/publications.pdf>

Version: 2024-02-01

185  
papers

7,593  
citations

57758

44  
h-index

60623

81  
g-index

186  
all docs

186  
docs citations

186  
times ranked

6701  
citing authors

#	ARTICLE	IF	CITATIONS
1	Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. <i>Lancet, The</i> , 2011, 378, 1396-1407.	13.7	1,007
2	Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 615-621.	3.8	362
3	Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. <i>Blood</i> , 2010, 115, 1886-1892.	1.4	315
4	Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. <i>American Journal of Hematology</i> , 2017, 92, 1068-1078.	4.1	290
5	Iron deficiency anaemia revisited. <i>Journal of Internal Medicine</i> , 2020, 287, 153-170.	6.0	233
6	Non-transfusion-dependent thalassemias. <i>Haematologica</i> , 2013, 98, 833-844.	3.5	231
7	Optimal management of $\beta^2$ thalassaemia intermedia. <i>British Journal of Haematology</i> , 2011, 152, 512-523.	2.5	187
8	$\beta^2$ -Thalassemias. <i>New England Journal of Medicine</i> , 2021, 384, 727-743.	27.0	183
9	Clinical experience with fetal hemoglobin induction therapy in patients with $\beta^2$ -thalassemia. <i>Blood</i> , 2013, 121, 2199-2212.	1.4	154
10	Elevated liver iron concentration is a marker of increased morbidity in patients with $\beta^2$ thalassemia intermedia. <i>Haematologica</i> , 2011, 96, 1605-1612.	3.5	153
11	Smoking and the Risk of Mortality and Vascular and Respiratory Events in Patients Undergoing Major Surgery. <i>JAMA Surgery</i> , 2013, 148, 755.	4.3	140
12	Bone disease and skeletal complications in patients with $\beta^2$ thalassemia major. <i>Bone</i> , 2011, 48, 425-432.	2.9	127
13	Splenectomy and thrombosis: the case of thalassemia intermedia. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2152-2158.	3.8	120
14	Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. <i>Blood</i> , 2012, 120, 440-448.	1.4	107
15	Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. <i>Blood Reviews</i> , 2012, 26, S16-S19.	5.7	105
16	$\beta^2$ -Thalassemia Intermedia: A Clinical Perspective. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a013482-a013482.	6.2	102
17	Prevalence and Risk Factors for Pulmonary Arterial Hypertension in a Large Group of $\beta^2$ -Thalassemia Patients Using Right Heart Catheterization. <i>Circulation</i> , 2014, 129, 338-345.	1.6	101
18	Age-related complications in treatment-naïve patients with thalassaemia intermedia. <i>British Journal of Haematology</i> , 2010, 150, 486-489.	2.5	100

#	ARTICLE	IF	CITATIONS
19	Fetal hemoglobin levels and morbidity in untransfused patients with $\beta^2$ -thalassemia intermedia. <i>Blood</i> , 2012, 119, 364-367.	1.4	85
20	Iron deficiency beyond erythropoiesis: should we be concerned?. <i>Current Medical Research and Opinion</i> , 2018, 34, 81-93.	1.9	83
21	Cerebral infarction in $\beta^2$ -thalassemia intermedia: Breaking the silence. <i>Thrombosis Research</i> , 2012, 130, 695-702.	1.7	81
22	Impact of Preoperative Anaemia and Blood Transfusion on Postoperative Outcomes in Gynaecological Surgery. <i>PLoS ONE</i> , 2015, 10, e0130861.	2.5	80
23	Serum ferritin levels and endocrinopathy in medically treated patients with $\beta^2$ thalassemia major. <i>Annals of Hematology</i> , 2012, 91, 1107-1114.	1.8	79
24	Redefining thalassemia as a hypercoagulable state. <i>Annals of the New York Academy of Sciences</i> , 2010, 1202, 231-236.	3.8	78
25	ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1556-1565.	3.8	74
26	Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 54-59.	3.8	72
27	Renal complications in transfusion-dependent beta thalassaemia. <i>Blood Reviews</i> , 2010, 24, 239-244.	5.7	70
28	Hypercoagulability in $\beta^2$ -thalassemia: a status quo. <i>Expert Review of Hematology</i> , 2012, 5, 505-512.	2.2	70
29	Treating iron overload in patients with non-transfusion-dependent thalassemia. <i>American Journal of Hematology</i> , 2013, 88, 409-415.	4.1	67
30	Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. <i>British Journal of Haematology</i> , 2009, 146, 569-572.	2.5	66
31	Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II. <i>Blood</i> , 2011, 118, 894-898.	1.4	62
32	Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. <i>American Journal of Hematology</i> , 2010, 85, 288-290.	4.1	61
33	Iron Overload: Consequences, Assessment, and Monitoring. <i>Hemoglobin</i> , 2009, 33, S46-S57.	0.8	59
34	Mechanisms of Renal Disease in $\beta^2$ -Thalassemia. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1299-1302.	6.1	58
35	Risk factors for pulmonary hypertension in patients with $\beta^2$ thalassemia intermedia. <i>European Journal of Internal Medicine</i> , 2011, 22, 607-610.	2.2	56
36	Serum ferritin level and morbidity risk in transfusion-independent patients with $\beta^2$ -thalassemia intermedia: the ORIENT study. <i>Haematologica</i> , 2014, 99, e218-e221.	3.5	56

#	ARTICLE	IF	CITATIONS
37	Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study. <i>Annals of Hematology</i> , 2010, 89, 585-589.	1.8	55
38	Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with $\beta^2$ thalassemia intermedia. <i>Blood Cells, Molecules, and Diseases</i> , 2011, 47, 232-234.	1.4	55
39	Ineffective Erythropoiesis: Anemia and Iron Overload. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 213-221.	2.2	54
40	Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. <i>Thrombosis Research</i> , 2009, 123, 679-686.	1.7	53
41	Cross-Talk between Available Guidelines for the Management of Patients with Beta-Thalassemia Major. <i>Acta Haematologica</i> , 2013, 130, 64-73.	1.4	49
42	Evaluation of the 5mg/g liver iron concentration threshold and its association with morbidity in patients with $\beta^2$ -thalassemia intermedia. <i>Blood Cells, Molecules, and Diseases</i> , 2013, 51, 35-38.	1.4	47
43	Brain magnetic resonance angiography in splenectomized adults with $\beta^2$ -thalassemia intermedia. <i>European Journal of Haematology</i> , 2011, 87, 539-546.	2.2	46
44	Iron overload and chelation therapy in myelodysplastic syndromes. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 64-73.	4.4	46
45	Hypercoagulability in non-transfusion-dependent thalassemia. <i>Blood Reviews</i> , 2012, 26, S20-S23.	5.7	44
46	Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. <i>American Journal of Hematology</i> , 2015, 90, 91-96.	4.1	43
47	Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions. <i>British Journal of Haematology</i> , 2017, 176, 288-299.	2.5	43
48	Iron deficiency in chronic heart failure: case-based practical guidance. <i>ESC Heart Failure</i> , 2018, 5, 764-771.	3.1	43
49	Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with $\beta^2$ -thalassemia intermedia. <i>Blood Cells, Molecules, and Diseases</i> , 2012, 49, 136-139.	1.4	42
50	Iron overload in $\beta^2$ -thalassemia intermedia. <i>Current Opinion in Hematology</i> , 2013, 20, 187-192.	2.5	42
51	Ratio Between Positive Lymph Nodes and Total Excised Axillary Lymph Nodes as an Independent Prognostic Factor for Overall Survival in Patients with Nonmetastatic Lymph Node-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2009, 16, 3388-3395.	1.5	41
52	Thrombosis in Thalassemia: Why are we so Concerned?. <i>Hemoglobin</i> , 2011, 35, 503-510.	0.8	40
53	Contemporary approaches to treatment of beta-thalassemia intermedia. <i>Blood Reviews</i> , 2012, 26, S24-S27.	5.7	40
54	The effect of maternal fasting during Ramadan on preterm delivery: a prospective cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2012, 119, 1379-1386.	2.3	40

#	ARTICLE	IF	CITATIONS
55	THALASSEMIA AND VENOUS THROMBOEMBOLISM. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011025.	1.3	39
56	Health-related quality of life in adults with transfusion-independent thalassaemia intermedia compared to regularly transfused thalassaemia major: new insights. European Journal of Haematology, 2011, 87, 73-79.	2.2	39
57	2021 update on clinical trials in $\beta^2$ -thalassemia. American Journal of Hematology, 2021, 96, 1518-1531.	4.1	38
58	Challenges Associated With Prolonged Survival of Patients With Thalassemia: Transitioning From Childhood to Adulthood. Pediatrics, 2008, 121, e1426-e1429.	2.1	34
59	Thalassaemia Intermedia: an Update. Mediterranean Journal of Hematology and Infectious Diseases, 2009, 1, e2009004.	1.3	34
60	Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease. European Journal of Haematology, 2009, 83, 565-571.	2.2	33
61	Insight onto the Pathophysiology and Clinical Complications of Thalassemia Intermedia. Hemoglobin, 2009, 33, S145-S159.	0.8	33
62	Overview of Iron Chelation Therapy with Desferrioxamine and Deferiprone. Hemoglobin, 2009, 33, S58-S69.	0.8	33
63	Aspirin Resistance. Advances in Hematology, 2009, 2009, 1-10.	1.0	32
64	Implementation of an Emergency Department Computer System: Design Features That Users Value. Journal of Emergency Medicine, 2011, 41, 693-700.	0.7	32
65	Is VEGF a predictive biomarker to anti-angiogenic therapy?. Critical Reviews in Oncology/Hematology, 2011, 79, 103-111.	4.4	31
66	Assessment and management of iron overload in $\beta^2$ -thalassaemia major patients during the 21st century: a real-life experience from the Italian Webthal project. British Journal of Haematology, 2013, 161, 872-883.	2.5	31
67	Glomerular Hyperfiltration and Proteinuria in Transfusion-Independent Patients with $\beta^2$ -Thalassemia Intermedia. Nephron, 2013, 121, c136-c143.	1.8	31
68	Postoperative Outcomes After Laparoscopic Splenectomy Compared With Open Splenectomy. Annals of Surgery, 2013, 257, 1116-1123.	4.2	29
69	The risk of local recurrence along the core-needle biopsy tract in patients with bone sarcomas. Iowa orthopaedic journal, The, 2010, 30, 80-3.	0.5	29
70	Revisiting the non-transfusion-dependent (NTDT) vs. transfusion-dependent (TDT) thalassemia classification 10 years later. American Journal of Hematology, 2021, 96, E54-E56.	4.1	28
71	Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease. Blood, 2010, 115, 2980-2981.	1.4	27
72	The Spine in $\beta^2$ -Thalassemia Syndromes. Spine, 2012, 37, 334-339.	2.0	27

#	ARTICLE	IF	CITATIONS
73	Brain positron emission tomography in splenectomized adults with $\beta^2$ -thalassemia intermedia: uncovering yet another covert abnormality. <i>Annals of Hematology</i> , 2012, 91, 235-241.	1.8	27
74	Survival and causes of death in 2,033 patients with non-transfusion-dependent $\beta^2$ -thalassemia. <i>Haematologica</i> , 2021, 106, 2489-2492.	3.5	25
75	Abdominal Manifestations of Multiple Myeloma: A Retrospective Radiologic Overview. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 348-351.	1.4	24
76	Prevalence of Depression and Anxiety in Adult Patients with $\beta^2$ -Thalassemia Major and Intermedia. <i>International Journal of Psychiatry in Medicine</i> , 2012, 44, 291-303.	1.8	24
77	Elevated prepartum fibrinogen levels are not associated with a reduced risk of postpartum hemorrhage. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1451-1453.	3.8	24
78	One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. <i>Pediatric Blood and Cancer</i> , 2017, 64, 188-196.	1.5	24
79	Childhood stroke in a child with familial Mediterranean fever carrying several prothrombotic risk factors. <i>Lupus</i> , 2009, 18, 845-847.	1.6	23
80	A closer look at paroxysmal nocturnal hemoglobinuria. <i>European Journal of Internal Medicine</i> , 2010, 21, 260-267.	2.2	23
81	Left ventricular noncompaction in patients with $\beta^2$ -thalassemia: Uncovering a previously unrecognized abnormality. <i>American Journal of Hematology</i> , 2012, 87, 1079-1083.	4.1	23
82	Establishment of a bleeding score as a diagnostic tool for patients with rare bleeding disorders. <i>Thrombosis Research</i> , 2016, 148, 128-134.	1.7	22
83	Preoperative INR and postoperative major bleeding and mortality: A retrospective cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 301-311.	2.1	22
84	Potential mechanisms for renal damage in beta-thalassemia. <i>Journal of Nephrology</i> , 2013, 26, 821-828.	2.0	22
85	Morbidity-free survival and hemoglobin level in non-transfusion-dependent $\beta^2$ -thalassemia: a 10-year cohort study. <i>Annals of Hematology</i> , 2022, 101, 203-204.	1.8	21
86	Hemoglobin level and morbidity in non-transfusion-dependent thalassemia. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 55, 108-109.	1.4	20
87	Hypercoagulability and Vascular Disease. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 237-245.	2.2	20
88	Variations in hemoglobin level and morbidity burden in non-transfusion-dependent $\beta^2$ -thalassemia. <i>Annals of Hematology</i> , 2021, 100, 1903-1905.	1.8	20
89	Risk of mortality from anemia and iron overload in nontransfusion-dependent $\beta^2$ -thalassemia. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	19
90	Primary colorectal lymphoma. <i>Medical Oncology</i> , 2010, 27, 249-254.	2.5	18

#	ARTICLE	IF	CITATIONS
91	Iron in sickle cell disease: What have we learned over the years?. <i>Pediatric Blood and Cancer</i> , 2011, 56, 182-190.	1.5	18
92	The emerging concept of residual ADAMTS13 activity in ADAMTS13-deficient thrombotic thrombocytopenic purpura. <i>Blood Reviews</i> , 2013, 27, 71-76.	5.7	17
93	The Hypercoagulable State in Thalassemia Intermedia. <i>Hemoglobin</i> , 2009, 33, S160-S169.	0.8	16
94	Correlation of non-mass-like abnormal MR signal intensity with pathological findings surrounding pediatric osteosarcoma and Ewing's sarcoma. <i>Skeletal Radiology</i> , 2012, 41, 1453-1461.	2.0	16
95	Postoperative outcomes following pancreaticoduodenectomy: how should age affect clinical practice?. <i>World Journal of Surgical Oncology</i> , 2013, 11, 131.	1.9	16
96	Solitary mediastinal lymph node metastasis in rectosigmoid carcinoma: a case report. <i>Cases Journal</i> , 2008, 1, 69.	0.4	15
97	Iron chelation therapy for patients with sickle cell disease and iron overload. <i>American Journal of Hematology</i> , 2010, 85, 782-786.	4.1	15
98	Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia. <i>European Journal of Internal Medicine</i> , 2016, 28, 91-96.	2.2	14
99	Recent advances and treatment challenges in patients with non-transfusion-dependent thalassemia. <i>Blood Reviews</i> , 2012, 26, S1-S2.	5.7	13
100	Preventing Thalassemia in Lebanon: Successes and Challenges in a Developing Country. <i>Hemoglobin</i> , 2014, 38, 308-311.	0.8	13
101	Serum ferritin values between 300 and 800 ng/mL in nontransfusion-dependent thalassemia: A probability curve to guide clinical decision making when MRI is unavailable. <i>American Journal of Hematology</i> , 2017, 92, E35-E37.	4.1	13
102	Long-term improvement in cardiac magnetic resonance in $\beta^0$ -thalassemia major patients treated with deferasirox extends to patients with abnormal baseline cardiac function. <i>American Journal of Hematology</i> , 2019, 94, 312-318.	4.1	13
103	Antibiotic use and risk of gynecological cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2011, 159, 388-393.	1.1	12
104	Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with $\alpha$ -thalassemia major. <i>Haematologica</i> , 2013, 98, 555-559.	3.5	12
105	Relationship between transfusion burden, healthcare resource utilization, and complications in patients with beta-thalassemia in Taiwan: A real-world analysis. <i>Transfusion</i> , 2021, 61, 2906-2917.	1.6	12
106	Management of non-transfusion-dependent $\beta^0$ -thalassemia (<sc>NTDT</sc>): The next 5 years. <i>American Journal of Hematology</i> , 2021, 96, E57-E59.	4.1	11
107	Serum Ferritin Levels and Morbidity in $\beta^0$ -Thalassemia Intermedia: A 10-Year Cohort Study. <i>Blood</i> , 2012, 120, 1021-1021.	1.4	11
108	The impact of zoledronic acid on regenerate and native bone after consolidation and removal of the external fixator: An animal model study. <i>Bone</i> , 2010, 46, 363-368.	2.9	10

#	ARTICLE	IF	CITATIONS
109	Iron Chelation Therapy for Transfusional Iron Overload: A Swift Evolution. Hemoglobin, 2011, 35, 565-573.	0.8	10
110	Mortality in $\beta^2$ -thalassemia patients with confirmed pulmonary arterial hypertension on right heart catheterization. Blood, 2022, 139, 2080-2083.	1.4	10
111	Sickle Cell Disease at the Dawn of the Molecular Era. Hemoglobin, 2009, 33, S93-S106.	0.8	9
112	Hepatitis C antiviral response in thalassemia: what is the role of liver iron concentration?. Annals of Hematology, 2009, 88, 1033-1034.	1.8	9
113	Preoperative Pneumonia and Postoperative Venous Thrombosis: A Cohort Study of 427,656 Patients Undergoing Major General Surgery. World Journal of Surgery, 2016, 40, 1288-1294.	1.6	9
114	Less "reds"™ more "blues"™: hemoglobin level and depression in non-transfusion-dependent thalassemia. Annals of Hematology, 2020, 99, 903-904.	1.8	9
115	Transfusion independence in Diamond-Blackfan anemia after deferasirox therapy. Annals of Hematology, 2009, 88, 1263-1264.	1.8	8
116	Carbamazepine-induced thrombocytopenia. Blood Cells, Molecules, and Diseases, 2012, 48, 197-198.	1.4	8
117	End stage renal disease in six patients with beta-thalassemia intermedia. Blood Cells, Molecules, and Diseases, 2013, 51, 146-148.	1.4	8
118	A liver mass in an iron-overloaded thalassaemia intermedia patient. British Journal of Haematology, 2013, 161, 1-1.	2.5	8
119	Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): A status quo. Blood Cells, Molecules, and Diseases, 2014, 52, 88-90.	1.4	8
120	Primary $\alpha$ -HBB gene mutation severity and long-term outcomes in a global cohort of $\beta^2$ -thalassaemia. British Journal of Haematology, 2022, 196, 414-423.	2.5	8
121	Silent Brain Abnormalities in Thalassemia Intermedia: A Combined MRI/PET Study.. Blood, 2009, 114, 4077-4077.	1.4	8
122	Pulmonary Complications of Sickle Cell Disease. Hemoglobin, 2011, 35, 625-635.	0.8	7
123	Cerebral Infarction in Children with Sickle Cell Disease: A Concise Overview. Hemoglobin, 2011, 35, 618-624.	0.8	7
124	Preoperative Hematocrit Concentration and the Risk of Stroke in Patients Undergoing Isolated Coronary-Artery Bypass Grafting. Anemia, 2013, 2013, 1-7.	1.7	7
125	A killer revealed: 10-year experience with beta-thalassemia intermedia. Hematology, 2014, 19, 196-198.	1.5	7
126	Development of a thalassemia-related thrombosis risk scoring system. American Journal of Hematology, 2019, 94, E207-E209.	4.1	7



#	ARTICLE	IF	CITATIONS
127	Burkitt's lymphoma of the colon and bronchi: three case reports. <i>Cases Journal</i> , 2008, 1, 15.	0.4	6
128	Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major. <i>Haematologica</i> , 2011, 96, e5-e6.	3.5	6
129	von Willebrand factor propeptide to antigen ratio in acquired thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 728-730.	3.8	6
130	Thalassemia and autoimmune diseases: Absence of evidence or evidence of absence?. <i>Blood Reviews</i> , 2022, 52, 100874.	5.7	6
131	Solitary Hydatid Cyst of the Thigh: A Challenging Diagnosis. <i>Vector-Borne and Zoonotic Diseases</i> , 2009, 9, 743-745.	1.5	5
132	High-output cardiac failure secondary to a large arteriovenous fistula: a persistent threat to the dialysis and kidney transplant patient. <i>CKJ: Clinical Kidney Journal</i> , 2009, 2, 147-148.	2.9	5
133	Small bowel intussusception following blunt abdominal trauma in an adult patient. <i>Emergency Medicine Journal</i> , 2009, 26, 752-753.	1.0	5
134	Does absolute excess of alpha chains compromise the benefit of splenectomy in patients with thalassemia intermedia?. <i>Haematologica</i> , 2012, 97, 151-153.	3.5	5
135	Emerging Therapies. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 343-352.	2.2	5
136	Distinctive Presentation of a Diaphragmatic Hernia 15 Years After A Traumatic Insult. <i>Annals of Thoracic Surgery</i> , 2009, 88, 651-653.	1.3	4
137	Covert brain ischaemia in splenectomised adults with thalassemia intermedia: An emerging entity. <i>Thrombosis and Haemostasis</i> , 2010, 104, 652-653.	3.4	4
138	Molecular Spectra and Frequency Patterns of Somatic Mutations in Arab Women with Breast Cancer. <i>Oncologist</i> , 2021, 26, e2086-e2089.	3.7	4
139	Prevalence and Risk Factors of Left Ventricular Noncompaction in Patients with $\beta^2$ -Thalassemia.. <i>Blood</i> , 2012, 120, 2127-2127.	1.4	4
140	Effects of divalproex sodium on hemoglobin level. <i>Blood Cells, Molecules, and Diseases</i> , 2009, 43, 49-52.	1.4	3
141	Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall survival in patients with nonmetastatic lymph node-positive breast cancer. <i>Indian Journal of Surgical Oncology</i> , 2010, 1, 68-75.	0.7	3
142	Predicting venous thromboembolism in hospitalized medical patients: are we there yet?. <i>Expert Review of Hematology</i> , 2011, 4, 1-3.	2.2	3
143	Sequential Therapy with Gemcitabine and Carboplatin Followed by Paclitaxel as First Line Treatment for Advanced Urothelial Cancer. <i>Journal of Cancer</i> , 2012, 3, 362-368.	2.5	3
144	Deferiprone-induced seizures in a patient with $\beta^2$ -thalassemia major. <i>Blood Cells, Molecules, and Diseases</i> , 2013, 51, 94-95.	1.4	3

#	ARTICLE	IF	CITATIONS
145	Random Forest Clustering Identifies Three Subgroups of $\beta^2$ -Thalassemia with Distinct Clinical Severity. <i>Thalassemia Reports</i> , 2022, 12, 14-23.	0.5	3
146	Iron and hepatitis C: What can we learn from thalassemia major?. <i>Liver International</i> , 2008, 28, 892-893.	3.9	2
147	Malignancy and hypercoagulability: a two-way association revisited. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 340-341.	2.1	2
148	JAK2V617F and Prothrombin G20210A Gene Mutations in a Patient With Budd-Chiari Syndrome and Essential Thrombocythemia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010, 16, 472-474.	1.7	2
149	Managing unresponsiveness or intolerance to deferasirox therapy: a tale of two doses. <i>Expert Review of Hematology</i> , 2011, 4, 411-414.	2.2	2
150	ANTITHROMBOTIC PROPHYLAXIS IN THE MIDDLE EAST. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011023.	1.3	2
151	Case report: use of thienopyridines in a patient with acquired idiopathic thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 416-418.	2.1	2
152	Mondor's Disease of the Breast in the Context of Inherited Thrombophilia. <i>Breast Journal</i> , 2012, 18, 373-374.	1.0	2
153	Switching patients from warfarin to dabigatran therapy: To RE-LY or not to rely. <i>International Journal of Cardiology</i> , 2012, 154, e27-e28.	1.7	2
154	Iron overload in non-transfusion-dependent thalassemia. <i>Thalassemia Reports</i> , 2013, 3, 11.	0.5	2
155	On the use of substandard medicines in hematology: An emerging concern in the Middle East and North Africa region. <i>European Journal of Internal Medicine</i> , 2018, 48, e40-e41.	2.2	2
156	1-Year Results From A Prospective Randomized Trial Comparing Phlebotomy with Deferasirox for the Treatment of Iron Overload in Pediatric Patients with Thalassemia Major Following Curative Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 904-904.	1.4	2
157	Elevated Hematocrit Concentration and the Risk of Mortality and Vascular Events in Patients Undergoing Major Surgery.. <i>Blood</i> , 2012, 120, 2088-2088.	1.4	2
158	A novel genotype c.1228C>G/c.1448C-1498C (L371V/Rec-Ncil) in a 3-year-old child with type 1 Gaucher disease. <i>Journal of Applied Genetics</i> , 2008, 49, 421-424.	1.9	1
159	Axillary Lymph Node Ratio Revisited. <i>Journal of Clinical Oncology</i> , 2009, 27, e67-e67.	1.6	1
160	Antiphospholipid Syndrome, Microalbuminuria, and Risk of Venous Thromboembolism. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 945.	7.4	1
161	Clinical images: Severe photosensitive skin reaction secondary to an herbal treatment in a patient with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009, 60, 2854-2854.	6.7	1
162	The use of biological therapy in refractory rheumatic diseases other than rheumatoid arthritis: experience at a tertiary care center in Lebanon. <i>Rheumatology International</i> , 2009, 29, 1255-1257.	3.0	1

#	ARTICLE	IF	CITATIONS
163	Thromboangiitis obliterans and the inherited thrombophilias: does an association merit consideration?. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 223-224.	1.0	1
164	The role of liver iron in hepatitis C antiviral treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 769.	1.6	1
165	The wanderer. <i>American Journal of Obstetrics and Gynecology</i> , 2010, 202, 662.e1.	1.3	1
166	A new chelator in the house. <i>Blood</i> , 2012, 119, 3191-3192.	1.4	1
167	Association between cardiac T2* magnetic resonance imaging values and endocrine function tests in patients with $\beta^2$ -thalassemia major. <i>Blood Cells, Molecules, and Diseases</i> , 2014, 52, 50-51.	1.4	1
168	Iron Overload Indices In Thalassemia Major Children Cured by Stem Cell Transplantation at Enrollment In a Prospective Randomized Trial Comparing Phlebotomy and Deferasirox. <i>Blood</i> , 2010, 116, 2082-2082.	1.4	1
169	Evaluation of the 5 Mg/g Liver Iron Concentration Threshold and Its Association with Vascular and Endocrine/Bone Morbidity in $\beta^2$ -Thalassemia Intermedia. <i>Blood</i> , 2012, 120, 1024-1024.	1.4	1
170	Greater Red Blood Cell Transfusion Burden Is Associated with More Healthcare Resource Utilization in Patients with Beta-Thalassemia. <i>Blood</i> , 2019, 134, 5790-5790.	1.4	1
171	A Phase 2a Study Evaluating the Safety and Pharmacokinetics (PK) of Luspatercept in Pediatric Patients with Transfusion-Dependent $\beta^2$ -Thalassemia (TDT). <i>Blood</i> , 2021, 138, 4161-4161.	1.4	1
172	Caught up with Time. <i>Digestive Surgery</i> , 2009, 26, 24-24.	1.2	0
173	Re: Anti-Angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1657-1657.	6.3	0
174	Pregnancy and risk of venous thromboembolism in developing countries. <i>British Journal of Haematology</i> , 2009, 146, 691-692.	2.5	0
175	Recombinant Activated Factor VII in Abdominal Aortic Emergencies. <i>Annals of Surgery</i> , 2009, 249, 692.	4.2	0
176	Thrombotic renal and adrenal manifestations of primary antiphospholipid syndrome. <i>Rheumatology International</i> , 2010, 30, 993-994.	3.0	0
177	Use of Recombinant Activated Factor VII for Intractable Bleeding in Patients Without Hemophilia: A Developing Country Tertiary Care Center's Experience. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010, 16, 658-662.	1.7	0
178	A computed tomography Iron Index. <i>European Journal of Radiology</i> , 2010, 75, 189-190.	2.6	0
179	Adverse operative outcomes in patients with anaemia – Authors' reply. <i>Lancet, The</i> , 2012, 379, 1299-1300.	13.7	0
180	Risk Factors for Pulmonary Hypertension In Patients with Thalassemia Intermedia. <i>Blood</i> , 2010, 116, 2069-2069.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Prevalence of Anxiety and Depression In Transfusion-Independent Thalassemia Intermedia Compared to Regularly-Transfused Patients with Thalassemia Major. Blood, 2010, 116, 5167-5167.	1.4	0
182	Coagulation Factor Activity Level and Clinical Bleeding Severity in Rare Bleeding Disorders: Results From the European Network of Rare Bleeding Disorders (EN-RBD),. Blood, 2011, 118, 3312-3312.	1.4	0
183	Iron Chelation Therapy and Mobilization of Hematopoietic Peripheral Progenitors in Patients with $\beta^2$ -Thalassemia Major. Blood, 2012, 120, 5178-5178.	1.4	0
184	Assessment and Management of Iron Overload in $\beta^2$ -Thalassemia Major Patients in Italy: A Real-Life Experience From the Webthal <sup>®</sup> Project. Blood, 2012, 120, 1030-1030.	1.4	0
185	Estimation of the Prevalence of Pulmonary Artery Hypertension in a Large Group of $\beta^2$ -Thalassemia Patients Using Right Heart Catheterization. Blood, 2012, 120, 3262-3262.	1.4	0